title: Anemia of chronic kidney disease: Treat it, but not too aggressively.
abstract: Anemia of renal disease is common and is associated with significant morbidity and death. It is mainly caused by a decrease in erythropoietin production in the kidneys and can be partially corrected with erythropoiesis-stimulating agents (ESAs). However, randomized controlled trials have shown that using ESAs to target normal hemoglobin levels can be harmful, and have called into question any benefits of ESA treatment other than avoidance of transfusions.
authors: Department of Nephrology and Hypertension, Glickman Urological and Kidney institute, Cleveland Clinic, Cleveland, OH, USA.
authors: Georges
authors: G
authors: Nakhoul
authors: Department of Nephrology and Hypertension, Glickman Urological and Kidney institute, Cleveland Clinic, Cleveland, OH, USA. E-mail: simonj2@ccf.org.|Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
authors: James F
authors: JF
authors: Simon
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000378:metabolism; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: C554270:EPO protein, human; D006397:Hematinics; D004921:Erythropoietin